Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration.

摘要: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in USA. The treatment locally advanced NSCLC (LA-NSCLC) challenging and must be individualized. For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4 cycles recommended. inoperable or unresectable chemoradiation preferred treatment. Patients a good performance status, minimal no weight loss, adequate pulmonary function should offered concurrent chemoradiation. optimal chemotherapeutic agents to used concurrently radiation remain undefined. In USA, cisplatin plus etoposide carboplatin paclitaxel are most commonly regimens. addition, duration therapy remains undefined, including role consolidation chemotherapy. Thus far, randomized phase trials have failed identify survival advantage administering beyond that delivered during therapy. Molecularly targeted agents, angiogenesis inhibitors, immunotherapy defined metastatic disease. role, if any, these new classes undergoing investigation earlier disease,